 Charles Daley
Concepts (459)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Mycobacterium Infections, Nontuberculous | 92 | 2025 | 352 | 17.170 |
Why?
| | Mycobacterium abscessus | 36 | 2025 | 107 | 8.670 |
Why?
| | Mycobacterium avium-intracellulare Infection | 27 | 2025 | 61 | 8.420 |
Why?
| | Mycobacterium avium Complex | 42 | 2025 | 88 | 8.050 |
Why?
| | Nontuberculous Mycobacteria | 50 | 2024 | 203 | 7.020 |
Why?
| | Lung Diseases | 42 | 2025 | 742 | 6.700 |
Why?
| | Anti-Bacterial Agents | 62 | 2025 | 1717 | 5.760 |
Why?
| | Antitubercular Agents | 38 | 2024 | 200 | 5.590 |
Why?
| | Tuberculosis | 32 | 2024 | 272 | 5.140 |
Why?
| | Tuberculosis, Pulmonary | 25 | 2021 | 135 | 4.440 |
Why?
| | Tuberculosis, Multidrug-Resistant | 13 | 2024 | 57 | 3.460 |
Why?
| | Mycobacterium Infections | 12 | 2019 | 62 | 3.370 |
Why?
| | Mycobacterium kansasii | 10 | 2020 | 15 | 3.070 |
Why?
| | Mycobacterium | 15 | 2023 | 106 | 2.860 |
Why?
| | Bronchiectasis | 18 | 2025 | 108 | 2.760 |
Why?
| | Mycobacterium tuberculosis | 26 | 2019 | 308 | 2.740 |
Why?
| | Cystic Fibrosis | 20 | 2023 | 1053 | 2.670 |
Why?
| | Amikacin | 16 | 2025 | 23 | 2.560 |
Why?
| | Macrolides | 15 | 2023 | 63 | 2.410 |
Why?
| | Drug Resistance, Bacterial | 21 | 2023 | 176 | 2.050 |
Why?
| | Interferon-gamma Release Tests | 6 | 2016 | 32 | 1.900 |
Why?
| | Sputum | 25 | 2020 | 302 | 1.620 |
Why?
| | Microbial Sensitivity Tests | 25 | 2025 | 352 | 1.600 |
Why?
| | Disease Outbreaks | 6 | 2024 | 349 | 1.480 |
Why?
| | Humans | 192 | 2025 | 129652 | 1.330 |
Why?
| | Latent Tuberculosis | 8 | 2017 | 67 | 1.300 |
Why?
| | Pneumonia, Bacterial | 6 | 2017 | 115 | 1.250 |
Why?
| | AIDS-Related Opportunistic Infections | 4 | 2016 | 123 | 1.190 |
Why?
| | Clofazimine | 4 | 2021 | 15 | 1.140 |
Why?
| | Antibiotics, Antitubercular | 9 | 2021 | 37 | 1.130 |
Why?
| | Rifampin | 14 | 2024 | 85 | 1.120 |
Why?
| | Pneumonia | 5 | 2023 | 616 | 1.040 |
Why?
| | Clarithromycin | 13 | 2023 | 28 | 0.970 |
Why?
| | Boron Compounds | 1 | 2025 | 22 | 0.940 |
Why?
| | Drug Therapy, Combination | 19 | 2022 | 1040 | 0.910 |
Why?
| | HIV Infections | 15 | 2022 | 2720 | 0.890 |
Why?
| | Oxazolidinones | 3 | 2013 | 14 | 0.890 |
Why?
| | Acetamides | 3 | 2013 | 36 | 0.870 |
Why?
| | Global Health | 8 | 2018 | 329 | 0.860 |
Why?
| | Ethambutol | 10 | 2021 | 25 | 0.840 |
Why?
| | Tuberculin Test | 6 | 2016 | 36 | 0.780 |
Why?
| | Equipment Contamination | 2 | 2019 | 56 | 0.750 |
Why?
| | Aged | 53 | 2025 | 22104 | 0.720 |
Why?
| | Treatment Outcome | 31 | 2025 | 10230 | 0.720 |
Why?
| | Professional Practice Gaps | 1 | 2020 | 15 | 0.690 |
Why?
| | Disease Management | 4 | 2021 | 589 | 0.650 |
Why?
| | Middle Aged | 60 | 2025 | 31155 | 0.650 |
Why?
| | San Francisco | 10 | 2014 | 51 | 0.600 |
Why?
| | Molecular Epidemiology | 4 | 2006 | 63 | 0.590 |
Why?
| | Adult | 51 | 2025 | 35577 | 0.580 |
Why?
| | Female | 76 | 2025 | 68777 | 0.570 |
Why?
| | Algorithms | 1 | 2025 | 1622 | 0.560 |
Why?
| | Male | 76 | 2025 | 63682 | 0.560 |
Why?
| | Practice Guidelines as Topic | 7 | 2025 | 1501 | 0.530 |
Why?
| | Health Care Sector | 2 | 2013 | 23 | 0.520 |
Why?
| | Extensively Drug-Resistant Tuberculosis | 2 | 2013 | 6 | 0.510 |
Why?
| | United States | 31 | 2025 | 13903 | 0.510 |
Why?
| | Drug Resistance, Multiple, Bacterial | 4 | 2019 | 71 | 0.510 |
Why?
| | Lung | 16 | 2024 | 3931 | 0.500 |
Why?
| | Azithromycin | 6 | 2021 | 93 | 0.500 |
Why?
| | Phylogeny | 5 | 2021 | 852 | 0.500 |
Why?
| | Imipenem | 7 | 2024 | 18 | 0.490 |
Why?
| | Drug Synergism | 5 | 2024 | 371 | 0.490 |
Why?
| | Genome, Bacterial | 5 | 2021 | 134 | 0.480 |
Why?
| | Retrospective Studies | 28 | 2022 | 14518 | 0.470 |
Why?
| | World Health Organization | 3 | 2024 | 110 | 0.460 |
Why?
| | Linezolid | 4 | 2018 | 20 | 0.460 |
Why?
| | beta-Lactamase Inhibitors | 5 | 2024 | 6 | 0.440 |
Why?
| | Organ Transplantation | 2 | 2024 | 228 | 0.440 |
Why?
| | Communicable Disease Control | 1 | 2014 | 73 | 0.430 |
Why?
| | Sex Factors | 1 | 2019 | 1968 | 0.420 |
Why?
| | beta-Lactams | 2 | 2024 | 28 | 0.420 |
Why?
| | Serologic Tests | 1 | 2012 | 52 | 0.400 |
Why?
| | Professional Practice | 1 | 2012 | 63 | 0.390 |
Why?
| | Rifabutin | 2 | 2012 | 6 | 0.380 |
Why?
| | Antibiotic Prophylaxis | 1 | 2012 | 101 | 0.370 |
Why?
| | Opportunistic Infections | 1 | 2011 | 46 | 0.370 |
Why?
| | Pyrazinamide | 4 | 2021 | 11 | 0.360 |
Why?
| | Aged, 80 and over | 15 | 2025 | 7086 | 0.340 |
Why?
| | Occupational Health | 1 | 2013 | 192 | 0.340 |
Why?
| | Drug Administration Schedule | 8 | 2025 | 769 | 0.340 |
Why?
| | Recurrence | 10 | 2019 | 1007 | 0.330 |
Why?
| | Mass Screening | 3 | 2016 | 1149 | 0.330 |
Why?
| | Occupational Exposure | 1 | 2013 | 299 | 0.320 |
Why?
| | Administration, Inhalation | 6 | 2021 | 666 | 0.320 |
Why?
| | Incidence | 10 | 2019 | 2644 | 0.310 |
Why?
| | Cardiac Surgical Procedures | 3 | 2019 | 499 | 0.310 |
Why?
| | Antigens, Bacterial | 5 | 2012 | 119 | 0.290 |
Why?
| | Directly Observed Therapy | 2 | 2005 | 15 | 0.280 |
Why?
| | Azabicyclo Compounds | 2 | 2024 | 6 | 0.280 |
Why?
| | Europe | 3 | 2025 | 364 | 0.280 |
Why?
| | Cefoxitin | 3 | 2024 | 8 | 0.280 |
Why?
| | Cefuroxime | 2 | 2024 | 4 | 0.280 |
Why?
| | Carcinoma, Squamous Cell | 1 | 2012 | 626 | 0.280 |
Why?
| | Health Personnel | 3 | 2014 | 652 | 0.280 |
Why?
| | Disease Progression | 7 | 2025 | 2635 | 0.280 |
Why?
| | Quality of Life | 6 | 2025 | 2704 | 0.270 |
Why?
| | Tuberculosis, Pleural | 2 | 2003 | 6 | 0.270 |
Why?
| | Tomography, X-Ray Computed | 9 | 2020 | 2535 | 0.270 |
Why?
| | Cephalosporins | 2 | 2024 | 40 | 0.260 |
Why?
| | Morbidity | 2 | 2019 | 302 | 0.260 |
Why?
| | Genomics | 4 | 2021 | 716 | 0.250 |
Why?
| | Administration, Oral | 4 | 2025 | 786 | 0.250 |
Why?
| | Diarylquinolines | 2 | 2019 | 12 | 0.250 |
Why?
| | Antibodies, Monoclonal | 1 | 2012 | 1367 | 0.250 |
Why?
| | ROC Curve | 4 | 2020 | 503 | 0.250 |
Why?
| | Nebramycin | 1 | 2025 | 1 | 0.240 |
Why?
| | Oxazepines | 2 | 2025 | 5 | 0.240 |
Why?
| | Mutation | 5 | 2019 | 3717 | 0.240 |
Why?
| | Diagnostic Tests, Routine | 2 | 2019 | 102 | 0.240 |
Why?
| | Benzoxazoles | 2 | 2025 | 20 | 0.230 |
Why?
| | Disease Transmission, Infectious | 1 | 2005 | 55 | 0.230 |
Why?
| | Prospective Studies | 14 | 2023 | 7133 | 0.230 |
Why?
| | Dipeptidyl-Peptidase IV Inhibitors | 1 | 2025 | 45 | 0.230 |
Why?
| | Water Microbiology | 1 | 2005 | 85 | 0.230 |
Why?
| | DNA Fingerprinting | 1 | 2004 | 25 | 0.220 |
Why?
| | Risk Factors | 9 | 2019 | 9765 | 0.220 |
Why?
| | Contact Tracing | 1 | 2004 | 23 | 0.220 |
Why?
| | Arizona | 1 | 2024 | 78 | 0.220 |
Why?
| | Research | 2 | 2018 | 416 | 0.220 |
Why?
| | Boronic Acids | 1 | 2024 | 37 | 0.220 |
Why?
| | Alveolitis, Extrinsic Allergic | 1 | 2005 | 98 | 0.220 |
Why?
| | Self Administration | 1 | 2004 | 122 | 0.220 |
Why?
| | DNA, Bacterial | 3 | 2021 | 324 | 0.220 |
Why?
| | Biomedical Research | 5 | 2020 | 638 | 0.220 |
Why?
| | Mexico | 1 | 2024 | 190 | 0.210 |
Why?
| | Medical Tourism | 1 | 2023 | 9 | 0.210 |
Why?
| | Colorado | 5 | 2024 | 4421 | 0.210 |
Why?
| | Adolescent | 18 | 2025 | 20394 | 0.210 |
Why?
| | Registries | 5 | 2020 | 1896 | 0.210 |
Why?
| | Biomarkers | 3 | 2020 | 3973 | 0.210 |
Why?
| | London | 1 | 2023 | 45 | 0.210 |
Why?
| | Leprostatic Agents | 1 | 2022 | 5 | 0.210 |
Why?
| | Stem Cell Transplantation | 1 | 2024 | 166 | 0.210 |
Why?
| | Republic of Korea | 6 | 2019 | 29 | 0.200 |
Why?
| | Pneumonectomy | 2 | 2016 | 151 | 0.200 |
Why?
| | Dose-Response Relationship, Drug | 4 | 2025 | 2012 | 0.200 |
Why?
| | Forced Expiratory Volume | 6 | 2025 | 511 | 0.190 |
Why?
| | Lung Neoplasms | 2 | 2012 | 2344 | 0.190 |
Why?
| | Meningitis | 1 | 2023 | 80 | 0.190 |
Why?
| | Isoniazid | 4 | 2019 | 63 | 0.190 |
Why?
| | Spectinomycin | 1 | 2021 | 2 | 0.190 |
Why?
| | Thorax | 1 | 2022 | 42 | 0.190 |
Why?
| | Time Factors | 7 | 2020 | 6556 | 0.190 |
Why?
| | Young Adult | 11 | 2025 | 12427 | 0.190 |
Why?
| | Comorbidity | 4 | 2019 | 1547 | 0.190 |
Why?
| | Radiography, Thoracic | 3 | 2017 | 168 | 0.190 |
Why?
| | Cohort Studies | 8 | 2020 | 5420 | 0.180 |
Why?
| | Safety | 1 | 2003 | 331 | 0.180 |
Why?
| | Dipeptidyl-Peptidases and Tripeptidyl-Peptidases | 1 | 2020 | 6 | 0.180 |
Why?
| | Cluster Analysis | 4 | 2020 | 482 | 0.180 |
Why?
| | Peptidyl Transferases | 1 | 2020 | 7 | 0.170 |
Why?
| | Bacteriophages | 1 | 2022 | 93 | 0.170 |
Why?
| | Serine Proteases | 1 | 2020 | 20 | 0.170 |
Why?
| | Prevalence | 4 | 2019 | 2564 | 0.170 |
Why?
| | Respiratory Therapy | 1 | 2020 | 23 | 0.170 |
Why?
| | Follow-Up Studies | 5 | 2020 | 4897 | 0.170 |
Why?
| | Area Under Curve | 3 | 2020 | 304 | 0.160 |
Why?
| | Nitroimidazoles | 1 | 2019 | 9 | 0.160 |
Why?
| | Mycobacterium fortuitum | 1 | 2019 | 2 | 0.160 |
Why?
| | Oxazoles | 1 | 2019 | 30 | 0.160 |
Why?
| | Cost of Illness | 1 | 2021 | 278 | 0.160 |
Why?
| | Durable Medical Equipment | 1 | 2019 | 4 | 0.160 |
Why?
| | Genotyping Techniques | 1 | 2019 | 72 | 0.160 |
Why?
| | Bronchoscopy | 1 | 2020 | 216 | 0.160 |
Why?
| | Patient Selection | 1 | 2003 | 663 | 0.160 |
Why?
| | Anti-HIV Agents | 3 | 2016 | 754 | 0.160 |
Why?
| | Genotype | 6 | 2019 | 1839 | 0.150 |
Why?
| | Drug-Related Side Effects and Adverse Reactions | 1 | 2021 | 253 | 0.150 |
Why?
| | DNA Gyrase | 1 | 2018 | 12 | 0.150 |
Why?
| | Aza Compounds | 2 | 2010 | 13 | 0.150 |
Why?
| | Hematopoietic Stem Cell Transplantation | 1 | 2024 | 573 | 0.150 |
Why?
| | Tertiary Care Centers | 1 | 2019 | 151 | 0.150 |
Why?
| | Hospitals | 1 | 2023 | 637 | 0.150 |
Why?
| | Musculoskeletal Diseases | 1 | 2019 | 69 | 0.150 |
Why?
| | Respiratory System Agents | 1 | 2018 | 22 | 0.150 |
Why?
| | Patient Compliance | 3 | 2011 | 565 | 0.150 |
Why?
| | Internationality | 1 | 2019 | 149 | 0.150 |
Why?
| | Treatment Failure | 3 | 2019 | 340 | 0.150 |
Why?
| | Tuberculosis Vaccines | 2 | 2010 | 4 | 0.140 |
Why?
| | Biological Specimen Banks | 1 | 2018 | 98 | 0.140 |
Why?
| | Liposomes | 1 | 2018 | 168 | 0.140 |
Why?
| | Child | 11 | 2024 | 20883 | 0.140 |
Why?
| | Pulmonary Medicine | 1 | 2018 | 79 | 0.140 |
Why?
| | Salvage Therapy | 1 | 2018 | 134 | 0.140 |
Why?
| | alpha 1-Antitrypsin Deficiency | 1 | 2018 | 67 | 0.140 |
Why?
| | Elephants | 1 | 2017 | 5 | 0.140 |
Why?
| | Interferon-gamma | 4 | 2007 | 770 | 0.140 |
Why?
| | Fluoroquinolones | 3 | 2018 | 45 | 0.140 |
Why?
| | Agammaglobulinemia | 1 | 2017 | 33 | 0.140 |
Why?
| | Quinolines | 2 | 2010 | 156 | 0.140 |
Why?
| | Databases, Genetic | 1 | 2018 | 232 | 0.130 |
Why?
| | Prognosis | 5 | 2020 | 3794 | 0.130 |
Why?
| | Sensitivity and Specificity | 4 | 2020 | 1838 | 0.130 |
Why?
| | Kartagener Syndrome | 1 | 2016 | 30 | 0.130 |
Why?
| | Surgical Equipment | 1 | 2016 | 13 | 0.130 |
Why?
| | Immunologic Deficiency Syndromes | 1 | 2016 | 63 | 0.130 |
Why?
| | Genes, Bacterial | 1 | 2016 | 157 | 0.130 |
Why?
| | Levofloxacin | 1 | 2016 | 25 | 0.130 |
Why?
| | Public Health | 4 | 2016 | 484 | 0.130 |
Why?
| | Staphylococcal Infections | 2 | 2018 | 393 | 0.130 |
Why?
| | Surgical Wound Infection | 1 | 2019 | 283 | 0.120 |
Why?
| | Adrenal Cortex Hormones | 1 | 2019 | 522 | 0.120 |
Why?
| | Cough | 3 | 2023 | 116 | 0.120 |
Why?
| | Patient Outcome Assessment | 1 | 2016 | 125 | 0.120 |
Why?
| | Gene Expression Regulation | 2 | 2020 | 2548 | 0.120 |
Why?
| | Gene Expression Profiling | 2 | 2020 | 1706 | 0.120 |
Why?
| | Disease Models, Animal | 2 | 2024 | 4063 | 0.120 |
Why?
| | Clinical Trials as Topic | 3 | 2020 | 1004 | 0.120 |
Why?
| | Chronic Disease | 3 | 2023 | 1720 | 0.120 |
Why?
| | Drug Tolerance | 1 | 2015 | 90 | 0.110 |
Why?
| | Guidelines as Topic | 1 | 2016 | 264 | 0.110 |
Why?
| | Cross Infection | 1 | 2016 | 218 | 0.110 |
Why?
| | Antiretroviral Therapy, Highly Active | 2 | 2007 | 267 | 0.110 |
Why?
| | Sequence Analysis, DNA | 2 | 2014 | 779 | 0.110 |
Why?
| | Genetic Variation | 2 | 2021 | 937 | 0.110 |
Why?
| | DNA Transposable Elements | 2 | 2006 | 118 | 0.110 |
Why?
| | Double-Blind Method | 4 | 2025 | 1876 | 0.110 |
Why?
| | Patient Acceptance of Health Care | 2 | 2018 | 759 | 0.110 |
Why?
| | CD4 Lymphocyte Count | 2 | 2004 | 266 | 0.110 |
Why?
| | Computational Biology | 1 | 2018 | 599 | 0.110 |
Why?
| | Societies, Medical | 4 | 2020 | 751 | 0.110 |
Why?
| | Anti-Inflammatory Agents | 1 | 2017 | 480 | 0.110 |
Why?
| | beta-Lactamases | 2 | 2024 | 41 | 0.100 |
Why?
| | MicroRNAs | 1 | 2020 | 678 | 0.100 |
Why?
| | Patient-Centered Care | 1 | 2018 | 505 | 0.100 |
Why?
| | Glucocorticoids | 1 | 2017 | 575 | 0.100 |
Why?
| | Contraindications | 1 | 2012 | 90 | 0.100 |
Why?
| | Transcriptome | 2 | 2015 | 887 | 0.100 |
Why?
| | Models, Statistical | 1 | 2016 | 623 | 0.100 |
Why?
| | Randomized Controlled Trials as Topic | 1 | 2018 | 1368 | 0.100 |
Why?
| | Gene Expression Regulation, Bacterial | 1 | 2015 | 324 | 0.100 |
Why?
| | Glycolipids | 1 | 2012 | 42 | 0.100 |
Why?
| | Immunoenzyme Techniques | 1 | 2012 | 213 | 0.100 |
Why?
| | Antibodies, Bacterial | 1 | 2012 | 137 | 0.090 |
Why?
| | Cytokines | 2 | 2011 | 2017 | 0.090 |
Why?
| | Drug Resistance, Multiple | 1 | 2011 | 25 | 0.090 |
Why?
| | Consensus | 3 | 2022 | 616 | 0.090 |
Why?
| | Chemical and Drug Induced Liver Injury | 2 | 2003 | 132 | 0.090 |
Why?
| | Immunoglobulin A | 1 | 2012 | 200 | 0.090 |
Why?
| | Drug Interactions | 1 | 2012 | 394 | 0.090 |
Why?
| | Kaplan-Meier Estimate | 3 | 2019 | 857 | 0.090 |
Why?
| | Debridement | 1 | 2011 | 83 | 0.090 |
Why?
| | Virulence | 1 | 2011 | 255 | 0.090 |
Why?
| | Pulmonary Disease, Chronic Obstructive | 2 | 2018 | 985 | 0.090 |
Why?
| | Hospitals, General | 2 | 2014 | 21 | 0.090 |
Why?
| | Metagenomics | 2 | 2021 | 156 | 0.090 |
Why?
| | Bacterial Proteins | 2 | 2024 | 835 | 0.080 |
Why?
| | Case-Control Studies | 3 | 2020 | 3381 | 0.080 |
Why?
| | Respiratory Tract Infections | 1 | 2014 | 376 | 0.080 |
Why?
| | Hepatitis, Viral, Human | 1 | 2009 | 25 | 0.080 |
Why?
| | Forkhead Transcription Factors | 2 | 2007 | 185 | 0.080 |
Why?
| | Netherlands | 2 | 2012 | 77 | 0.080 |
Why?
| | Lung Transplantation | 1 | 2012 | 289 | 0.080 |
Why?
| | Bacteriological Techniques | 1 | 2009 | 69 | 0.080 |
Why?
| | Confidence Intervals | 2 | 2015 | 317 | 0.080 |
Why?
| | Interleukins | 2 | 2007 | 241 | 0.080 |
Why?
| | Vitamins | 1 | 2010 | 174 | 0.080 |
Why?
| | Proportional Hazards Models | 2 | 2019 | 1201 | 0.080 |
Why?
| | Hospitalization | 1 | 2018 | 2070 | 0.080 |
Why?
| | Child, Preschool | 4 | 2016 | 10517 | 0.080 |
Why?
| | Early Diagnosis | 1 | 2009 | 234 | 0.080 |
Why?
| | Radiography | 2 | 2008 | 798 | 0.070 |
Why?
| | Interleukin-9 | 1 | 2007 | 9 | 0.070 |
Why?
| | RNA, Ribosomal, 23S | 2 | 2018 | 13 | 0.070 |
Why?
| | Animals | 7 | 2024 | 35361 | 0.070 |
Why?
| | Logistic Models | 3 | 2019 | 1988 | 0.070 |
Why?
| | Survival Analysis | 2 | 2016 | 1274 | 0.070 |
Why?
| | Reagent Kits, Diagnostic | 1 | 2007 | 43 | 0.070 |
Why?
| | Interleukin-12 Subunit p40 | 1 | 2007 | 9 | 0.070 |
Why?
| | Pneumonia, Pneumococcal | 1 | 2007 | 42 | 0.070 |
Why?
| | Polysaccharides, Bacterial | 1 | 2007 | 67 | 0.070 |
Why?
| | Congresses as Topic | 2 | 2020 | 216 | 0.070 |
Why?
| | Th1 Cells | 1 | 2007 | 138 | 0.070 |
Why?
| | Polymorphism, Single Nucleotide | 3 | 2021 | 2073 | 0.070 |
Why?
| | Survivors | 1 | 2010 | 464 | 0.070 |
Why?
| | Vitamin D | 1 | 2010 | 384 | 0.070 |
Why?
| | Mice | 4 | 2024 | 16937 | 0.060 |
Why?
| | Age Factors | 3 | 2019 | 3144 | 0.060 |
Why?
| | Liver Function Tests | 2 | 2003 | 112 | 0.060 |
Why?
| | Interleukin-8 | 1 | 2007 | 262 | 0.060 |
Why?
| | Keratosis | 1 | 2025 | 16 | 0.060 |
Why?
| | Regression Analysis | 1 | 2008 | 993 | 0.060 |
Why?
| | Hydrotherapy | 1 | 2005 | 8 | 0.060 |
Why?
| | Bacterial Load | 1 | 2025 | 66 | 0.060 |
Why?
| | Coinfection | 2 | 2018 | 131 | 0.060 |
Why?
| | Antirheumatic Agents | 1 | 2007 | 278 | 0.060 |
Why?
| | Anti-Retroviral Agents | 1 | 2007 | 231 | 0.060 |
Why?
| | Immunosuppressive Agents | 1 | 2009 | 853 | 0.060 |
Why?
| | Microbial Viability | 1 | 2025 | 84 | 0.060 |
Why?
| | Surveys and Questionnaires | 1 | 2017 | 5406 | 0.060 |
Why?
| | Cost-Benefit Analysis | 2 | 2024 | 569 | 0.060 |
Why?
| | Mycobacterium xenopi | 2 | 2014 | 2 | 0.060 |
Why?
| | Streptomycin | 1 | 2003 | 16 | 0.060 |
Why?
| | Biopsy | 2 | 2005 | 1097 | 0.060 |
Why?
| | Respiratory Function Tests | 2 | 2016 | 586 | 0.060 |
Why?
| | Molecular Docking Simulation | 1 | 2024 | 109 | 0.050 |
Why?
| | Carrier State | 1 | 2004 | 60 | 0.050 |
Why?
| | Drug Evaluation, Preclinical | 1 | 2024 | 171 | 0.050 |
Why?
| | Medicare | 2 | 2019 | 720 | 0.050 |
Why?
| | Influenza, Human | 1 | 2009 | 601 | 0.050 |
Why?
| | Dust | 1 | 2023 | 94 | 0.050 |
Why?
| | Pseudomonas Infections | 2 | 2016 | 221 | 0.050 |
Why?
| | Homosexuality, Male | 1 | 2004 | 175 | 0.050 |
Why?
| | Staphylococcus aureus | 2 | 2018 | 438 | 0.050 |
Why?
| | Substance Abuse, Intravenous | 1 | 2004 | 108 | 0.050 |
Why?
| | Databases, Factual | 2 | 2019 | 1269 | 0.050 |
Why?
| | Predictive Value of Tests | 2 | 2007 | 1952 | 0.050 |
Why?
| | Tumor Necrosis Factor-alpha | 1 | 2007 | 1198 | 0.050 |
Why?
| | Survival Rate | 1 | 2007 | 1877 | 0.050 |
Why?
| | Transplant Recipients | 1 | 2024 | 162 | 0.050 |
Why?
| | Los Angeles | 1 | 2002 | 63 | 0.050 |
Why?
| | Drug Costs | 1 | 2003 | 100 | 0.050 |
Why?
| | Lactams | 1 | 2021 | 21 | 0.050 |
Why?
| | Peptidoglycan | 1 | 2021 | 26 | 0.050 |
Why?
| | Amoxicillin | 1 | 2022 | 30 | 0.050 |
Why?
| | Reproducibility of Results | 2 | 2020 | 3083 | 0.050 |
Why?
| | Phenotype | 2 | 2021 | 3076 | 0.050 |
Why?
| | Ambulatory Care | 1 | 2005 | 504 | 0.040 |
Why?
| | Clone Cells | 1 | 2021 | 261 | 0.040 |
Why?
| | Carboxypeptidases | 1 | 2020 | 13 | 0.040 |
Why?
| | Real-Time Polymerase Chain Reaction | 1 | 2021 | 331 | 0.040 |
Why?
| | Leukocyte Elastase | 1 | 2020 | 74 | 0.040 |
Why?
| | Water | 1 | 2023 | 448 | 0.040 |
Why?
| | Gene Ontology | 1 | 2020 | 51 | 0.040 |
Why?
| | Multivariate Analysis | 1 | 2003 | 1502 | 0.040 |
Why?
| | Chimera | 1 | 2019 | 59 | 0.040 |
Why?
| | Neutrophils | 1 | 2025 | 1205 | 0.040 |
Why?
| | Drug Monitoring | 2 | 2016 | 216 | 0.040 |
Why?
| | United States Food and Drug Administration | 1 | 2020 | 204 | 0.040 |
Why?
| | Medication Adherence | 1 | 2024 | 558 | 0.040 |
Why?
| | Public Health Surveillance | 1 | 2019 | 68 | 0.040 |
Why?
| | Stem Cells | 1 | 2023 | 577 | 0.040 |
Why?
| | Risk Assessment | 2 | 2019 | 3240 | 0.040 |
Why?
| | Cross-Over Studies | 1 | 2021 | 521 | 0.040 |
Why?
| | Population Surveillance | 1 | 2002 | 439 | 0.040 |
Why?
| | Mice, Inbred BALB C | 1 | 2021 | 1245 | 0.040 |
Why?
| | Meat | 1 | 2019 | 93 | 0.040 |
Why?
| | Molecular Diagnostic Techniques | 1 | 2019 | 98 | 0.040 |
Why?
| | Ribosomal Proteins | 1 | 2018 | 77 | 0.040 |
Why?
| | Prosthesis-Related Infections | 1 | 2019 | 75 | 0.040 |
Why?
| | Insurance Claim Review | 1 | 2018 | 64 | 0.040 |
Why?
| | Symptom Assessment | 1 | 2019 | 125 | 0.040 |
Why?
| | Gene Expression | 2 | 2016 | 1472 | 0.040 |
Why?
| | Gene Regulatory Networks | 1 | 2020 | 284 | 0.040 |
Why?
| | International Cooperation | 1 | 2018 | 174 | 0.030 |
Why?
| | Enzyme-Linked Immunosorbent Assay | 2 | 2011 | 833 | 0.030 |
Why?
| | Animals, Zoo | 1 | 2017 | 12 | 0.030 |
Why?
| | Methyltransferases | 1 | 2017 | 70 | 0.030 |
Why?
| | Otitis | 1 | 2016 | 9 | 0.030 |
Why?
| | Pseudomonas | 1 | 2016 | 28 | 0.030 |
Why?
| | Immunoglobulins | 1 | 2017 | 159 | 0.030 |
Why?
| | Drug Resistance, Microbial | 1 | 2016 | 69 | 0.030 |
Why?
| | Delivery of Health Care | 1 | 2023 | 894 | 0.030 |
Why?
| | Micronesia | 1 | 2016 | 3 | 0.030 |
Why?
| | Mycobacterium chelonae | 1 | 2016 | 8 | 0.030 |
Why?
| | Spirometry | 1 | 2016 | 257 | 0.030 |
Why?
| | Needs Assessment | 1 | 2018 | 360 | 0.030 |
Why?
| | Multiple Pulmonary Nodules | 1 | 2016 | 19 | 0.030 |
Why?
| | Host-Pathogen Interactions | 1 | 2019 | 352 | 0.030 |
Why?
| | Vital Capacity | 1 | 2016 | 292 | 0.030 |
Why?
| | Body Temperature Regulation | 1 | 2016 | 96 | 0.030 |
Why?
| | Bronchi | 1 | 2017 | 247 | 0.030 |
Why?
| | Injections, Intravenous | 1 | 2016 | 201 | 0.030 |
Why?
| | Drug Combinations | 1 | 2016 | 330 | 0.030 |
Why?
| | Clinical Decision-Making | 1 | 2018 | 303 | 0.030 |
Why?
| | Uganda | 1 | 2015 | 72 | 0.030 |
Why?
| | Rhinitis | 1 | 2016 | 152 | 0.030 |
Why?
| | Leukocytes, Mononuclear | 2 | 2007 | 545 | 0.030 |
Why?
| | Fibrosis | 1 | 2017 | 520 | 0.030 |
Why?
| | Insurance, Health | 1 | 2016 | 267 | 0.030 |
Why?
| | RNA, Messenger | 2 | 2015 | 2708 | 0.030 |
Why?
| | Research Design | 1 | 2020 | 1044 | 0.030 |
Why?
| | Gastroesophageal Reflux | 1 | 2016 | 232 | 0.030 |
Why?
| | Sinusitis | 1 | 2016 | 210 | 0.030 |
Why?
| | Sequence Homology, Nucleic Acid | 1 | 2013 | 150 | 0.030 |
Why?
| | False Positive Reactions | 1 | 2014 | 114 | 0.030 |
Why?
| | Mycobacterium avium | 1 | 2013 | 21 | 0.030 |
Why?
| | Greece | 1 | 2012 | 7 | 0.030 |
Why?
| | DNA, Ribosomal Spacer | 1 | 2012 | 6 | 0.030 |
Why?
| | Self Report | 1 | 2017 | 799 | 0.030 |
Why?
| | Mycolic Acids | 1 | 2012 | 7 | 0.030 |
Why?
| | Iran | 1 | 2012 | 38 | 0.020 |
Why?
| | Bacterial Typing Techniques | 1 | 2012 | 43 | 0.020 |
Why?
| | Geography | 1 | 2013 | 188 | 0.020 |
Why?
| | Italy | 1 | 2012 | 100 | 0.020 |
Why?
| | Sweden | 1 | 2012 | 93 | 0.020 |
Why?
| | DNA-Directed RNA Polymerases | 1 | 2012 | 56 | 0.020 |
Why?
| | Developing Countries | 2 | 2005 | 287 | 0.020 |
Why?
| | Cerebrospinal Fluid | 1 | 2012 | 93 | 0.020 |
Why?
| | Species Specificity | 1 | 2013 | 575 | 0.020 |
Why?
| | Heat-Shock Proteins | 1 | 2012 | 136 | 0.020 |
Why?
| | Protein Array Analysis | 1 | 2011 | 56 | 0.020 |
Why?
| | Microspheres | 1 | 2011 | 127 | 0.020 |
Why?
| | Drug Discovery | 1 | 2012 | 131 | 0.020 |
Why?
| | Bone Marrow Cells | 1 | 2012 | 300 | 0.020 |
Why?
| | Adaptation, Physiological | 1 | 2015 | 513 | 0.020 |
Why?
| | Pseudomonas aeruginosa | 1 | 2014 | 347 | 0.020 |
Why?
| | Referral and Consultation | 1 | 2016 | 733 | 0.020 |
Why?
| | Demography | 1 | 2011 | 279 | 0.020 |
Why?
| | Body Mass Index | 1 | 2019 | 2273 | 0.020 |
Why?
| | Postoperative Care | 1 | 2012 | 241 | 0.020 |
Why?
| | In Vitro Techniques | 1 | 2012 | 1085 | 0.020 |
Why?
| | Evolution, Molecular | 1 | 2014 | 466 | 0.020 |
Why?
| | RNA, Ribosomal, 16S | 1 | 2012 | 525 | 0.020 |
Why?
| | Preoperative Care | 1 | 2012 | 340 | 0.020 |
Why?
| | Hepatitis, Chronic | 1 | 2009 | 5 | 0.020 |
Why?
| | Anxiety | 1 | 2016 | 966 | 0.020 |
Why?
| | Fatty Acids | 1 | 2012 | 427 | 0.020 |
Why?
| | Age Distribution | 1 | 2010 | 372 | 0.020 |
Why?
| | Pleural Diseases | 1 | 2009 | 18 | 0.020 |
Why?
| | Smoking | 1 | 2016 | 1501 | 0.020 |
Why?
| | Sex Distribution | 1 | 2010 | 359 | 0.020 |
Why?
| | Cross-Sectional Studies | 2 | 2014 | 5066 | 0.020 |
Why?
| | Transcription, Genetic | 1 | 2015 | 1418 | 0.020 |
Why?
| | Age of Onset | 1 | 2010 | 496 | 0.020 |
Why?
| | Vulnerable Populations | 1 | 2009 | 158 | 0.020 |
Why?
| | False Negative Reactions | 1 | 2007 | 53 | 0.020 |
Why?
| | Molecular Sequence Data | 1 | 2012 | 2832 | 0.020 |
Why?
| | Depression | 1 | 2016 | 1307 | 0.020 |
Why?
| | Urinalysis | 1 | 2007 | 75 | 0.020 |
Why?
| | Lymphatic Diseases | 1 | 2007 | 21 | 0.020 |
Why?
| | Continuity of Patient Care | 1 | 2009 | 275 | 0.020 |
Why?
| | Cystic Fibrosis Transmembrane Conductance Regulator | 1 | 2010 | 312 | 0.020 |
Why?
| | Longitudinal Studies | 1 | 2014 | 2717 | 0.020 |
Why?
| | Bone Diseases | 1 | 2007 | 57 | 0.020 |
Why?
| | Forced Expiratory Flow Rates | 1 | 2006 | 14 | 0.020 |
Why?
| | Clinical Laboratory Techniques | 1 | 2007 | 94 | 0.020 |
Why?
| | Lung Diseases, Interstitial | 1 | 2012 | 616 | 0.020 |
Why?
| | Africa | 1 | 2006 | 99 | 0.020 |
Why?
| | Infection Control | 1 | 2007 | 140 | 0.020 |
Why?
| | Wounds and Injuries | 1 | 2012 | 711 | 0.020 |
Why?
| | Skin Diseases | 1 | 2007 | 143 | 0.010 |
Why?
| | India | 1 | 2005 | 170 | 0.010 |
Why?
| | C-Reactive Protein | 1 | 2007 | 401 | 0.010 |
Why?
| | Up-Regulation | 1 | 2007 | 840 | 0.010 |
Why?
| | Virus Latency | 1 | 2005 | 84 | 0.010 |
Why?
| | Dendritic Cells | 1 | 2007 | 478 | 0.010 |
Why?
| | Anti-Infective Agents | 1 | 2007 | 248 | 0.010 |
Why?
| | Quality of Health Care | 1 | 2009 | 608 | 0.010 |
Why?
| | Cost Savings | 1 | 2004 | 78 | 0.010 |
Why?
| | Diagnostic Techniques, Respiratory System | 1 | 2003 | 5 | 0.010 |
Why?
| | Pleura | 1 | 2003 | 22 | 0.010 |
Why?
| | Asthma | 1 | 2016 | 2230 | 0.010 |
Why?
| | HIV Seronegativity | 1 | 2003 | 25 | 0.010 |
Why?
| | Costs and Cost Analysis | 1 | 2004 | 201 | 0.010 |
Why?
| | Pleural Effusion | 1 | 2003 | 51 | 0.010 |
Why?
| | HIV Seropositivity | 1 | 2003 | 119 | 0.010 |
Why?
| | Infant | 1 | 2016 | 9024 | 0.010 |
Why?
| | Severity of Illness Index | 1 | 2010 | 2742 | 0.010 |
Why?
| | Mice, Inbred C57BL | 1 | 2012 | 5440 | 0.010 |
Why?
| | Chi-Square Distribution | 1 | 2003 | 516 | 0.010 |
Why?
| | Clinical Protocols | 1 | 2003 | 255 | 0.010 |
Why?
| | Health Policy | 1 | 2004 | 353 | 0.010 |
Why?
| | Data Interpretation, Statistical | 1 | 2003 | 335 | 0.010 |
Why?
| | Rural Population | 1 | 2005 | 518 | 0.010 |
Why?
| | Hypertension, Pulmonary | 1 | 2012 | 1894 | 0.010 |
Why?
| | Models, Theoretical | 1 | 2004 | 547 | 0.010 |
Why?
| | Liver | 1 | 2002 | 1839 | 0.010 |
Why?
|
|
Daley's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|